# Clinical Trials Data EGFR - Document 51

# Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

## Clinical Trial: https://clinicaltrials.gov/study/NCT02001896

"eligibilityCriteria": "Inclusion Criteria:\n\n\* adult patients, \\>=18 years of age;advanced (stage IIIB/IV)non-small cell lung cancer;measurable disease;ECOG Performance Status 0-2.\n\nExclusion Criteria:\n\n\* prior exposure to agents directed at the HER axis;prior chemotherapy or systemic anti-tumor therapy after advanced disease;unstable systemic disease; any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no specific mention of exclusions or inclusions based on EGFR gene mutation status. The inclusion criteria focus on the patient's age, stage of non-small cell lung cancer (stage IIIB/IV), measurable disease, and ECOG Performance Status. The exclusion criteria focus on prior treatments related to the HER axis, prior chemotherapy for advanced disease, unstable systemic disease, and recent malignancies.  
  
Since the EGFR mutation is not specifically mentioned as either an inclusion or exclusion factor, it suggests that a patient with an EGFR gene mutation could be eligible for this clinical trial, assuming they meet the other listed criteria and do not fall into any of the exclusions. However, to be certain, further details or consultation with the trial coordinators may be necessary.